- Messages
- 2,394
- Type of diabetes
- I reversed my Type 2
- Treatment type
- Diet only
The EMPA-REG study had positive CVD outcome and ignited interest in this class of T2D medication.
http://www.medscape.com/viewarticle/859551
But what I find encouraging is this view
Interesting how they reframe ketones when it is produced by SGLT2 inhibitors...
http://www.medscape.com/viewarticle/859551
But what I find encouraging is this view
http://www.medscape.com/viewarticle/866568?src=soc_tw_160804-pM_mscpedt_news_thoThe discussion and the argument have been about the possibility that the moderate rise in ketonemia that is observed in patients once they go on an SGLT2 inhibitor may be responsible for these metabolic changes by making available beta-hydroxybutyrate—a "super fuel"—because it can be taken up freely by both the kidney and the heart, and it is not insulin dependent. It can be utilized as a substrate to produce energy in a very efficient way; by efficient, one means using less oxygen for the same amount of adenosine triphosphate (ATP) produced, or conversely, using the same amount of oxygen to produce more ATP, to then be invested in contractility.
Interesting how they reframe ketones when it is produced by SGLT2 inhibitors...